Modern principles of conservative treatment of mild and moderate forms of ulcerative colitis

Ulcerative colitis is a chronic disease characterized by inflammation that usually begins in the rectum and diffusely spreads proximally, involving part or all of the colonic mucosa. The etiology of ulcerative colitis is still unknown, so there are no drugs that could cure this formidable disease. The entire vast arsenal of drugs that is offered for the treatment of ulcerative colitis is aimed at various, as yet insufficiently studied links in the pathogenesis of ulcerative colitis. The emergence of a new class of medicines (genetically engineered biological preparations), unfortunately, has not solved this cardinal problem. The only way to «cure» ulcerative colitis at present is to remove the entire colon with the formation of an ileoanal reservoir anastomosis or a permanent ileostomy. However, surgical treatment of ulcerative colitis is associated with many complications and sometimes death. The main goals of therapy for ulcerative colitis are to induce and maintain steroid-free clinical and endoscopic remission, reduce the incidence of complications, disability and improve the quality of life. Severe forms of ulcerative colitis requiring hospitalization and intensive conservative treatment, and sometimes surgery, account for about 15% of all cases of ulcerative colitis. Most mild to moderate forms of ulcerative colitis can be successfully treated on an outpatient basis with conventional medicines, most notably the innovative mesalazine. A competent combination of oral and rectal forms of mesalazine allows in most cases to achieve not only clinical remission, but to achieve the modern goal of treating ulcerative colitis – healing of the colon mucosa, that is, endoscopic remission. The article presents modern views on the treatment of mild and moderate forms of ulcerative colitis with different extent of colon damage, which are reflected in the latest domestic and foreign guidelines. 

1. Ng S. C., Shi H. Y., Hamidi N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies // Lancet. 2018; 390: 2769-2778. [PubMed: 29050646.]

2. Belousova E. A., Abdulganieva D. I., Alekseeva O. P., Alekseenko S. A., Baranovsky A. Yu., Valuiskikh E. Yu., Golovenko A. O., Golovenko O. V., Zhigalova T. N., Knyazev O. V., Kulyapin A.V., Lakhin A.V., Livzan M. A., Lubyanskaya T. G., Nikolaeva N. N., Nikitina N. V., Nikulina I. V., Osipenko M. F., Pavlenko V. V., Parfenov A. I., Rogachikov Yu. E., Svetlova I. O., Tkachev A. V., Tkachenko E. I., Khalif I. L., Chashkova E. Yu., Shchukina O. B., Yazenok N. S., Yakovlev A. A. Socio-demographic characteristics, features of the course and treatment options for inflammatory bowel diseases in Russia. Results of two multicenter studies // Almanakh klinicheskoi meditsiny. 2018. № 5.

3. Burisch J., Pedersen N., Cukovic-Cavka S., et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort // Inflamm Bowel Dis. 2014; 20: 36-46. [PubMed: 24252978].

4. Fumery M., Singh S., Dulai P. S., et al. Natural History of Adult Ulcerative Colitis in Populationbased Cohorts: A Systematic Review // Clin Gastroenterol Hepatol. 2017.

5. Ng S. C., Zeng Z., Niewiadomski O., et al. Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia // Gastroenterology. 2016; 150: 86-95 e3; quiz e13-4. [PubMed: 26385074.]

6. Niewiadomski O., Studd C., Hair C., et al. Prospective population-based cohort of inflammatory bowel disease in the biologics era: Disease course and predictors of severity // J Gastroenterol Hepatol. 2015; 30: 1346-53. [PubMed: 25867770.]

7. Samuel S., Ingle S. B., Dhillon S., et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 2013; 19: 1858-66. [PubMed: 23660997]

8. Solberg I. C., Lygren I., Jahnsen J., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) // Scand J Gastroenterol. 2009; 44: 431-440. [PubMed: 19101844].

9. Vegh Z., Burisch J., Pedersen N., et al. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort // J Crohns Colitis. 2015; 9: 156-163. [PubMed: 25518058] .

10. Frolkis A. D., Dykeman J., Negron M. E., et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies // Gastroenterology 2013; 145: 996-1006. [PubMed: 23896172.]

11. Golovenko A. O., Khalif I. L., Golovenko O. V., Veselov V. V. Predictors of infliximab efficacy in patients with severe attacks of ulcerative colitis // Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2013; 5 (23): 65-73.

12. Dassopoulos T., Cohen R. D., Scherl E. J., et al. Ulcerative Colitis Care Pathway // Gastroenterology. 2015; 149: 238-45. [PubMed: 26025078.]

13. Dias C. C., Rodrigues P. P., da Costa-Pereira A., et al. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies // J Crohns Colitis.

14. Khan N. H., Almukhtar R. M., Cole E. B., et al. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease – a nationwide study of 1035 patients // Aliment Pharmacol Ther. 2014; 40: 374-381. [PubMed: 24961751.]

15. Picco M. F., Krishna M., Cangemi J. R., et al. Oral mesalamine and clinical remission are associated with a decrease in the extent of longstanding ulcerative colitis // Inflamm Bowel Dis. 2006; 12: 537-442. [PubMed: 16804389.]

16. Sahami S., Konte K., Buskens C. J., et al. Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis // United European Gastroenterol J. 2017; 5: 554-562.

17. Torres J., Billioud V., Sachar D. B., et al. Ulcerative colitis as a progressive disease: the forgotten evidence // InflammBowel Dis. 2012; 18: 13561363. [PubMed: 22162423].

18. Gisbert J. P., Gomollon F., Hinojosa J., et al. Adherence of gastroenterologists to European Crohn’s and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain // J Crohns Colitis. 2010; 4: 567-574. [PubMed: 21122561.]

19. Singh S., Feuerstein J. D., Binion D. G., Tremaine W. J. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis // Gastroenterology. 2019; 156 (3): 769808. DOI: 10.1053/j.gastro.2018.12.008. Epub 2018 Dec 18. Erratum in: Gastroenterology. 2019; 157 (3): 903. PMID: 30576642; PMCID: PMC6858923.

20. Feuerstein J. D., Isaacs K. L., Schneider Y., Siddique S. M., Falck-Ytter Y., Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis // Gastroenterology. 2020; 158 (5): 1450-1461. DOI: 10.1053/j.gastro.2020.01.006. Epub 2020 Jan 13. PMID: 31945371; PMCID: PMC7175923.

21. Lamb C. A., Kennedy N. A., Raine T., Hendy P. A., Smith P. J., Limdi J. K., Hayee B., Lomer M. C. E., Parkes G. C., Selinger C., Barrett K. J., Davies R. J., Bennett C., Gittens S., Dunlop M. G., Faiz O., Fraser A., Garrick V., Johnston P. D., Parkes M., Sanderson J., Terry H; IBD guidelines eDelphi consensus group, Gaya D. R., Iqbal T. H., Taylor S. A., Smith M., Brookes M., Hansen R., Hawthorne A. B. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults // Gut. 2019; 68 (Suppl 3): s1-s106. DOI: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27. Erratum in: Gut. 2021; 70 (4): 1. PMID: 31562236; PMCID: PMC6872448.

22. PeyriОng Therapeutic Goals for Treat-toTarget // Am. J. Gastroenterol. 2015, 110, 13241338. [CrossRef] [PubMed].

23. Raine T., Bonovas S., Burisch J., Kucharzik T., Adamina M., Annese V., Bachmann O., Bettenworth D., Chaparro M., Czuber-Dochan W., et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment // J. Crohn’s Colitis. 2022; 16: 2-17. [CrossRef] [PubMed].

24. Kim K. O. Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice // Clin Endosc. 2022; 55 (4): 480-488. DOI: 10.5946/ce.2022.108. Epub 2022 Jul 28. PMID: 35898147; PMCID: PMC9329646.

25. Laharie D., Filippi J., Roblin X., et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: A multicenter experience // Aliment Pharmacol Ther. 2013. DOI: 10.1111/apt.12289.

26. Leung C. M., Tang W., Kyaw M., et al. Endoscopic and histological mucosal healing in ulcerative colitis in the first year of diagnosis: results from a population-based inception cohort from six countries in Asia // J Crohns Colitis 2017; 11: 1440-1448.

27. Theede K., Kiszka-Kanowitz M., NordgaardLassen I., Mertz Nielsen A. The impact of endoscopic inflammation and mucosal healing on health-related quality of life in ulcerative colitis patients // J Crohns Colitis. 2015; 9: 625-632.

28. Walsh A., Palmer R., Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity // Gastrointest Endosc Clin N Am. 2014; 24 (3): 367-378. DOI: 10.1016/j.giec.2014.03.005. Epub 2014 May 6. PMID: 24975528.

29. Belousova Ye. A., Nikitina N. V., Tsodikova O. M. Treatment of mild and moderate ulcerative colitis // Farmateka. 2013; 2: 42-46.

30. Clinical guidelines – Ulcerative colitis – 2020 (22.07.2020). Approved by the Ministry of Health of the Russian Federation. https://www.cr.minzdrav.gov.ru

31. Khalif I. L. Therapeutic tactics in ulcerative colitis // Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2006; 3 (16): 58-62.

32. Harris M. S., Lichtenstein G. R. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis // Aliment Pharmacol Ther. 2011; 33: 996-1009.

33. Ford A. C., Achkar J. P., Khan K. J., et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis // Am J Gastroenterol. 2011; 106: 601-616.

34. Iacucci M., de Silva S., Ghosh S. Mesalazine in inflammatory bowel disease: A trendy topic once again? // Can. J. Gastroenterol. 2010; 24: 127-133. [CrossRef].

35. Das K. M., Dubin R. Clinical pharmacokinetics of sulphasalazine // Clin Pharmacokinet. 1976; 1 (6): 406-425.

36. Register of medicines of Russia. Encyclopedia of drugs. 28-y vyp. M.: RLS-MEDIA, 2020. Р. 1368.

37. Kruis W.., Kiudelis G., Racz I. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, noninferiority trial // Gut. 2009; 58 (2): 233-240.

38. Leifeld L., Pfutzer R., Morgenstern J., Gibson P. R., Marakhouski Y., Greinwald R., Mueller R., Kruis W. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysis // Aliment Pharmacol Ther. 2011; 34 (9): 1115-1122.

39. Yuichiro O., Kan U., Hirotaka K., Eri M., Moe Y., Yuma A., Toshimune W., Sachie K., Sizuka S., Yoshihiro M., Zensho I., Toshifumi O., Shigeo K., Masayuki S. The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis // BMC Gastroenterol. 2022; 22 (1): 390. DOI: 10.1186/s12876-022-02474-9. PMID: 35982420; PMCID: PMC9389853.

40. Gross V., Bunganic I., Belousova E. A., et al. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, doubledummy, randomised trial // J Crohns Colitis. 2011; 5: 129-138.

41. Pokrotnieks J, Marlicz K, Paradowski L, Margus B, Zaborowski P, Greinwald R. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther. 2000 Sep;14(9):1191-8. doi: 10.1046/j.1365-2036.2000.00784.x. PMID: 10971236.

42. Rectal therapy of inflammatory bowel diseases / P. Fray, G. Rogler, A. O. Golovenko, S. I. Sitkin. M.: Prima Print, 2017. 28 s.: il. ISBN 978-5-9500690-0-0.

43. Frühmorgen P., Demling L. On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon // Hepatogastroenterology. 1980; 27: 473-476.

44. Marteau P, Probert C. S., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: A randomised, double blind, placebo controlled study // Gut. 2005. DOI: 10.1136/gut.2004.060103.

45. Safdi M., DeMicco M., Sninsky C., et al. A doubleblind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis // Am J Gastroenterol. 1997. DOI: 10.1016/0016-5085(95)27940-7.

46. Vecchi M., Meucci G., Gionchetti P., et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, doubledummy, randomized multicentre study // Aliment Pharmacol Ther. 2001; 15: 251-256.

47. Bar-Meir et al. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis // Dis Colon Rectum. 2003; 46: 929-936.

48. Hanauer S. B., Robinson M., Pruitt R., et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study // Gastroenterology. 1998. DOI: 10.1016/S0016-5085 (98)70131-3.

49. Sandborn W. J., Bosworth B., Zakko S., et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis // Gastroenterology. 2015. DOI: 10.1053/j.gastro.2015.01.037.

50. Mulder C. J., Fockens P., Meijer J. W., van der Heide H., Wiltink E. H., Tytgat G. N. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis // Eur J Gastroenterol Hepatol. 1996; 8: 549-553.

51. Qiu X., Ma J., Wang K., Zhang H. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: A systematic review with meta-analysis // Oncotarget. 2017. DOI: 10.18632/oncotarget.13715.

52. Chibbar R., Moss A. C. Mesalamine in the Initial Therapy of Ulcerative Colitis // Gastroenterol Clin North Am. 2020 Dec; 49 (4).

53. Lichtenstein G. R., Gordon G. L., Zakko S., Murthy U., Sedghi S., Pruitt R., Barrett A. C., Bortey E., Paterson C., Forbes W. P. Long-Term Benefi t of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission // Dig Dis Sci. 2016; 61 (1): 221-229. DOI: 10.1007/s10620-015-3866-7.

54. Maaser C., Sturm A., Vavricka S. R., et al. ECCOESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications // J Crohns Colitis. 2019; 13 (2): 144-164. DOI: 10.1093/ecco-jcc/jjy113.

55. Golovenko O. V., Khomeriki S. G., Ivanova Ye. V. i dr. Inflammatory bowel diseases: clinical, endoscopic, morphological aspects of diagnosis, principles of modern therapy. 2-ye izdaniye, dop. i pererab. M.: Prima Print, 2022. p 258.: il. ISBN 978-5-6046641-3-1.

56. Yokoyama H., Takagi S., Kuriyama S., Takahashi S., Takahashi H., Iwabuchi M., Takahashi S., Kinouchi Y., Hiwatashi N., Tsuji I., Shimosegawa T. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study // Inflamm Bowel Dis. 2007; 13 (9): 1115-1120.

57. Mahon SM. Colorectal cancer screening: Using evidence-based guidelines. Nurse Pract. 2017 Oct 18;42(10):18-26. DOI: 10.1097/01.NPR.0000524663.78727.4e. PMID: 28926493.